The long-term success of national efforts to reduce breast cancer incidence and mortality rests in part on the ability of Breast Cancer SPORE programs to attract and build the translational research careers of talented young faculty. Since 1992, the UNC Breast Cancer SPORE has used career development funds to promote the breast cancer research careers of selected investigators. The SPORE Career Enhancement Program (CEP) both recruits externally and identifies internal faculty with interest in translational breast cancer research. The CEP then matches junior faculty with training offerings and senior mentors. We seek to enrich the field with our efforts to recruit qualified women and minorities as both participants and mentors in the program. Over the 24 years of the program recruits funded by the CEP include 17 women and six minority faculty (three African Americans, three Hispanic). Co-recruitment with departments across campus attracts exceptional talent to UNC and its Cancer Center. The SPORE CEP makes available extended training for junior faculty with an interactive group of respected and successful investigators who can influence and help build careers. The combination of an excellent talent pool and an effective training and mentoring program has resulted in an elite cadre of breast cancer researchers whose work contributes to the national breast cancer effort. Over the last six years the CEP has attracted 13 participants; five were women and three were minorities. We are particularly pleased that six of the 13 recruits were named Komen Career Catalyst Scholars (as was one DRP Awardee) and several have already been funded by NCI. These CEP participants? contributions include published research, funded grants and collaborative breast cancer research across the spectrum of population, basic, clinical and translational research. Over the course of the CEP program a number of participants have become SPORE leaders. These include Bob Millikan, who developed CBCS; Charles Perou, Multi-PI and co- leader of Project 3; Lisa Carey Co-program head and co-leader of Projects 1 and 3 and the Career Enhancement Program; Melissa Troester, co-leader of Project 1; Carey Anders, clinical trial leader of Project #4; Claire Dees co-investigator on Project #2 and Katie Hoadley co-investigator Project #1, #3 and the Bioinformatics / Biostatistics Core. Over the next five years, the UNC Breast Cancer SPORE will continue to promote and develop careers in translational breast cancer research. The UNC Breast Cancer SPORE requests $50,000 to support career development. These funds will combine with $400-600,000 yearly in institutional funds to provide for recruitment and career development of faculty in translational breast cancer research. The SPORE leaders will continue to identify, recruit, and develop minority and women faculty.

Public Health Relevance

Career Development Program Project Narrative The Career Development Program of the UNC Breast SPORE prepares the next generation of translational breast cancer researchers. A successful Program of training, recruitment, and mentoring has brought 13 participants to the UNC Breast Cancer SPORE over the last cycle; five were women and three were minorities. Their success is noted by publications, new grants, with six of them being awarded Komen Career Catalyst Awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-24A1
Application #
9487503
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:

Showing the most recent 10 out of 598 publications